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e write in reference to the recent article in the Journal, the 2009
ppropriate Use Criteria for Cardiac Radionuclide Imaging
RNI), which was published by the American College of Cardi-
logy and endorsed by many other professional societies (1). This
ocument was anticipated to impact physician decision making,
est performance, and reimbursement policy.
We find the use of RNI for asymptomatic patients with diabetes
ellitus (patients 40 years old) and other coronary risk equiva-
ents that were considered appropriate in that document without
ufficient evidence. Diabetic patients have a high incidence of
oronary artery disease (CAD); therefore, an intensive primary and
econdary prevention is recommended by various professional
ocieties. But the strategy of routine RNI for all asymptomatic
atients cannot be considered appropriate. The DIAD (Detection
f Ischemia in Asymptomatic Diabetics) study was a prospective
andomized trial evaluating outcomes after screening for asymp-
omatic CAD in type 2 diabetic patients (2). Although the study
as underpowered to detect the pre-specified difference, due to a
ow rate of cardiac events, it ruled out any major benefit of routine
creening. Even moderate or large defects had a positive predictive
alue of just 12% for cardiac events. Also, there was no apparent
ifference in the use of interventions for risk modifications between
he 2 groups based upon results of screening. The recent BARI 2D
Bypass Angioplasty Revascularization Investigation in Type 2
iabetes) trial, which randomly assigned patients with type 2
iabetes and stable CAD to immediate revascularization with
ntensive medical therapy versus only intensive medical therapy,
ailed to show to any difference in mortality or major cardiovascular
vents (3). The COURAGE (Clinical Outcomes Utilizing Revas-
ularization and Aggressive Drug Evaluation) trial also showed
hat percutaneous intervention with optimal medical therapy was
o better than optimal medical therapy alone for patients with
table CAD in general and for a subgroup of patients with diabetes
pecifically (4).
Thus, so far, revascularization has not proven beneficial for
atients with asymptomatic or stable patients with CAD in terms
f mortality and major cardiac events. A possible benefit of relief
rom angina does not hold true for subjects who are asymptomatic
t baseline. In all of these trials, large proportions of patients in
oth groups received aggressive evidence-based interventions for
ardiovascular risk reduction as recommended by various profes-
ional societies, and that could explain the low event rates. So, if an
ggressive risk reduction strategy for asymptomatic high-risk
atients can lead to a substantial decrease in cardiac events without
ny additional benefit from revascularization, the role of additional
ardiac RNI is unclear. Routine RNI can be of use, if we can
dentify a subgroup of asymptomatic patients with additional risk
actors who can benefit from revascularization or screening. The
merican Diabetic Association acknowledges the dearth of evi-
ence in support of screening asymptomatic diabetic patients for
AD, and deemed it controversial (5). oThe Centers for Disease Control estimates that about 33.9% of
he U.S. population older than 40 years of age have diabetes (6). As
er the appropriate use criteria, these patients would represent a
igh-risk group for whom cardiac RNI would be considered
ppropriate. In most places, a cardiac RNI would cost about U.S.
700 to $1,400. That would put enormous pressure on health care
esources without any clear benefit.
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e greatly appreciate the comments of Dr. Sethi and colleagues
egarding the use of radionuclide imaging (RNI) in an asymptom-
tic but high-risk patient, such as one with diabetes mellitus, which
onstitutes one of the indications noted in the recently published RNI
ppropriate use criteria (AUC) (1). Their letter correctly describes the
ow event rate noted in the DIAD (Detection of Ischemia in
symptomatic Diabetics) study (2). Furthermore, information from
he BARI-2D (Bypass Angioplasty Revascularization Investigation in
ype 2 Diabetes) study (3), as well as that from the COURAGE
Clinical Outcomes Utilizing Revascularization and Aggressive Drug
valuation) study (4), fails to support the benefit of revascularization,
t least with regard to major cardiovascular events. At the present
ime, diabetic patients are still considered by clinical practice guide-
ines to be a high-risk/coronary artery disease-equivalent cohort,
lthough that may change in the future. However, neither the
ARI-2D study nor the DIAD study data were available at the time
f the rating for the radionuclide AUC. Additionally, both of these
